INSIGHT

R&D Tax Credit Strategies for Pre-Revenue Biotech Companies

Archie Thomas, Andre Shevchuck • May 27, 2026

Services: R&D Tax Credit Industries: Life Sciences

---

Building a biotech company before you’ve earned your first dollar of revenue is an exercise in calculated risk. Your burn rate is real, your runway is finite, and every funding source matters. Most early-stage founders know about venture capital and grants, but far fewer take full advantage of R&D tax credits, a non-dilutive funding source specifically designed for companies doing the R&D work they would otherwise be doing.

You don’t need to be profitable to benefit. Changes to federal tax law over the past decade have made R&D credits increasingly accessible to pre-revenue biotech companies, and several states have followed suit with their own programs. This article walks through how the federal R&D payroll tax offset works, what state-level opportunities exist, and how to build a documentation strategy that holds up under scrutiny.

The Federal R&D Payroll Tax Offset: Cash Now, Not Later

For years, R&D credits were largely theoretical for pre-revenue companies. If you’re generating losses, an income tax credit doesn’t do much for you. That changed when Congress introduced the payroll tax offset for qualified small businesses, a mechanism that lets startups apply R&D credits directly against their federal payroll tax liability on a quarterly basis. 

To qualify, your company must have less than $5 million in gross receipts for the current year and must not have been generating revenue for more than five years. If you meet both criteria, you can elect to apply a total of up to $500,000 per year in R&D credits. The first $250,000 of credits are applied against the employer portion of Social Security taxes, and the second $250,000 of credits are applied against Medicare taxes 

Here’s what that looks like in practice. Say your company has $2 million in qualified R&D expenses for the year. Using a conservative 8% credit rate, that generates a $160,000 credit. Once you file your corporate return, that credit starts offsetting your quarterly payroll taxes, resulting in real cash savings that stay in the business. 

Worth noting, any excess credits above $500,000 that you don’t use against payroll taxes are used against income tax expense or will otherwise carry forward for up to 20 years if no taxable income exists in the current year. If your company is eventually acquired or goes public, those accumulated credits could offset future income tax liability. 

What Qualifies as R&D in a Biotech Context

The federal R&D credit applies to activities that meet a four-part test: the work must be technological in nature, involve new product development or improvements made to existing products, address genuine technical uncertainties, and require substantially all of the related activities involving a process of experimentation. Biotech companies, by definition, are doing this kind of work, but that doesn’t mean every dollar spent automatically qualifies. 

Wages paid to scientists and lab staff working on qualifying projects are largely included, as are supply costs tied to experiments, prototype development, along with payments to outside contractors performing U.S.-based research. Clinical trial expenses sit in more complicated territory; the federal rules generally exclude trials conducted after technological uncertainty has been resolved, though the line isn’t always clean. 

The activities companies miss most often are the ones that don’t look like traditional research but still qualify:

• Assay development
• Manufacturing process optimization and scale-up development
• Formulation work
• Certain analytical testing
• Pre-commercialization quality improvements

Companies that define their qualifying activities too narrowly leave money on the table year after year.

State Credits: A Layer Most Companies Skip

Multiple states now offer R&D tax credit programs, and a handful are particularly valuable for pre-revenue companies because they offer refundable or transferable credits, meaning you can capture cash value even without tax liability.  

A few worth knowing: Massachusetts runs a Life Sciences Tax Incentive Program that includes refundable R&D credits equal to qualifying FDA user fees. Arizona offers refundable R&D credits for qualifying in-state activities provided the taxpayer meets certain eligibility requirements. California also offers an R&D credit generally at 15% of qualified research expenses incurred for California R&D activities. 

Each state has its own qualification rules, documentation requirements, and filing procedures. Some require pre-approval before you incur expenses. Others have strict deadlines that don’t align with your tax return due date. Missing these steps can mean forfeiting credits entirely, regardless of whether your underlying research clearly qualifies. 

Angel Investor Credits: A Bonus for Your Backers

Some states have taken their incentive programs a step further by creating tax credits for investors in qualifying early-stage companies. These programs won’t fund your research directly, but they can make your company a more attractive investment, which matters when you’re raising a seed or Series A round. 

• New Jersey’s Angel Investor Tax Credit Program offers a refundable credit for investments in emerging technology businesses, including biotechnology businesses.  
• New Mexico allows accredited investors to claim a credit of up to $62,500 per qualified investment in qualified New Mexico businesses conducting qualifying research, with a five-year carryforward for any unused portion.  

These programs change frequently, so confirming current rules with a qualified advisor before relying on them is essential. 

Documentation: The Part That Actually Determines Your Outcome

Having qualifying research and claiming a defensible credit are two different things. State and federal audits of R&D credits have grown more sophisticated, and auditors expect contemporaneous documentation, meaning records captured as the work happens, not reconstructed months later when the credit is being calculated. 

For a pre-revenue biotech company, building good documentation habits early pays off significantly. Focus on capturing: 

• Which employees are working on qualifying projects and what percentage of their time qualifies 
• The specific research initiatives for which each of the employees are conducting testing 
• Supply and third-party vendor activity costs tied to specific projects 
• The technical uncertainties driving each research initiative 
• Experimental hypotheses evaluated and tested against to resolve technical uncertainties, and the outcomes of each effort 

Strong records don’t just protect you during an audit; they also may surface qualifying activities you might otherwise overlook. 

Working with BPM

BPM offers R&D tax credit services to pre-revenue biotech companies across the country to identify, calculate, and document at both the federal and state level. Our team understands the life sciences industry, both the science behind the work and the tax rules that apply to it, helping companies maximize qualifying activities while building documentation that holds up under review.

If you’re investing in research and development before reaching revenue, your company may already qualify for credits you haven’t claimed. Contact BPM to learn what opportunities may be available.